Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03569098 · ClinicalTrials.gov registry record · Phase 2
Dysport in Hallux Abducto Valgus (HAV) Phase IIa
A Phase 2 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
NCT03569098 is a Phase 2 study that has completed, run by Ipsen. The registered enrollment target is 186 participants.
The verdict
NCT03569098, a Phase 2 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy and safety of treatment with multiple doses of Dysport in adults suffering from clinically significant pain associated with HAV who have not undergone surgery for their condition.
Interventions
- DRUG Placebo
- BIOLOGICAL Botulinum toxin type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2020-05-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03569098
The ClinicalTrials.gov registry entry for NCT03569098 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03569098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03569098 about?
NCT03569098 is a clinical study titled "Dysport in Hallux Abducto Valgus (HAV) Phase IIa". The purpose of this study is to investigate the efficacy and safety of treatment with multiple doses of Dysport in adults suffering from clinically significant pain associated with HAV who have not undergone surgery for their condition.
What is the current status of trial NCT03569098?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2018-06-19. Estimated completion is 2020-05-22.
What interventions are being tested in trial NCT03569098?
The interventions under investigation include: Placebo (DRUG), Botulinum toxin type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT03569098?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.